https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Dalpiciclib Plus Endocrine Therapy Prolonged Invasive Disease-Free Survival in HR+/HER2– Breast Cancer

Dalpiciclib Plus Endocrine Therapy Prolonged Invasive Disease-Free Survival in HR+/HER2– Breast Cancer

Dalpiciclib combined with endocrine therapy significantly enhances progression-free survival in HR+/HER2– breast cancer, as shown in the DAWNA-A trial.

administrator

Related Articles